U PDATE 51: A PRIL 1 TO A PRIL 30, 2013
PDP F UNDERS G ROUP
F
A
(
A
1, 2013)
4 April 2013:
On March 20, 2013, the Department of Biotechnology (DBT) of India, its Biotechnology Industry
Research Assistance Council (BIRAC), and the Bill & Melinda Gates Foundation launched Grand
Challenges India. Through this partnership, the government and the foundation will co-fund projects that aim to harness Indian innovation and research, and direct scientific discovery to develop affordable, sustainable solutions that improve health in India and around the world.
“We are proud to partner with BIRAC because we believe India is uniquely positioned to be a global leader in the development of new technologies and innovative approaches to achieve sustainable gains in development and health,” said Steven Buchsbaum, Deputy Director on the Discovery &
Translational Sciences team at the Bill & Melinda Gates Foundation. “Under the Memorandum of
Understanding that was signed last year, the DBT and the Gates Foundation have agreed to invest up to $ 25 Million each over 5 years in innovations in vaccines, drugs, agricultural products, and interventions related to malnutrition, family and child health.”
DBT and BIRAC join a global network of partners already using the Grand Challenges framework to foster collaborative research to improve global health and development. The Bill & Melinda Gates
Foundation recognizes that solving our greatest global health and development issues is a long-term effort. Through Grand Challenges, the foundation along with other Grand Challenges partners such as USAID , Grand Challenges Canada , and Grand Challenges Brazil, are committed to seeking out and rewarding not only established researchers in science and technology, but also young investigators, entrepreneurs, and other innovators to help expand the pipeline of ideas to fight diseases that claim millions of lives each year.
17 April 2013:
The Bill & Melinda Gates Foundation today announced that Brian Arbogast has been named director of the Water, Sanitation & Hygiene program. He will start work at the foundation on May 13, 2013. …
Arbogast was previously with Microsoft Corporation. Most recently, he concentrated in cleantech and international development to drive market solutions that address the world’s most pressing challenges. He served as a Senior Advisor with The Boston Consulting Group and as a board member of the Northwest Energy Angels. He is a founding board member of Progress Alliance of Washington.
He has served on the board of Water1st International and as a senior advisor to Upaya Social
Ventures.
17 April 2013:
The Bill & Melinda Gates Foundation is now accepting nominations for the third annual Gates Vaccine
Innovation Award.
The award aims to recognize, celebrate, and spur transformative ideas for improving health through the delivery of vaccines. Nominations will be accepted through July 31,
2013. …
By focusing on the delivery of vaccines, the Gates Vaccine Innovation Award aims to complement other awards focused on scientific research and development. The foundation will recognize the winning innovation with a USD $250,000 prize, which is allocated between the Award winner and an organization that can further improve vaccine delivery. …
22 April 2013:

U PDATE 51: A PRIL 1 TO A PRIL 30, 2013
More than 300 global leaders, health and development experts, vaccinators, celebrities, philanthropists, and business leaders will gather tomorrow in Abu Dhabi in the first Global Vaccine
Summit to endorse the critical role that vaccines and immunization play in giving children a healthy start to life. Despite tremendous progress, one child still dies every 20 seconds from preventable diseases like pneumonia, rotavirus, measles, and meningitis. …
25 April 2013:
Dato Sri Dr. Tahir, chairman of the Tahir Foundation in Indonesia, and Bill Gates, co-chair of the Bill &
Melinda Gates Foundation, announced today that their foundations are entering into a partnership to improve the lives of the world’s poorest. The partnership commits a total of US$200 million over five years – US$100 million from each partner – toward achieving the Millennium Development Goals.
The initial focus of their collaboration is support of the Global Polio Eradication Initiative’s (GPEI) new
Polio Eradication and Endgame Strategic Plan (2013-2018), designed to achieve a polio-free world by
2018. The comprehensive plan was developed to capitalize on the unprecedented opportunity to eradicate polio and is projected to cost $5.5 billion over six years. The Tahir Foundation is committing
US$25 million to help fund the plan. As part of its overall commitment to polio eradication announced today, the Gates Foundation matched the pledge. …
The partnership with the Tahir Foundation represents the Gates Foundation’s first major private donor partnership in Indonesia and will expand the focus of its work in Indonesia. Additional areas of the partnership’s focus will be tuberculosis, malaria and HIV and family planning. The foundations agreed to share learnings and seek out opportunities to co-fund projects that will accelerate their mutual goals, as well as to encourage philanthropy from Asia and globally. The Gates Foundation has funded a number of programs in Indonesia, including its Global Libraries program. …
25 April 2013:
Today, at the Global Vaccine Summit, the Global Polio Eradication Initiative (GPEI) presented a comprehensive six-year plan, the first plan to eradicate all types of polio disease – both wild poliovirus and vaccine-derived cases – simultaneously. Global leaders and individual philanthropists signaled their confidence in the plan by pledging close to three-quarters of the plan’s projected
US$5.5 billion cost over six years. They also called upon additional donors to commit up front the additional US$1.5 billion needed to ensure eradication. …
25 April 2013
Carlos Slim announced today that his foundation will donate $100 million to help end polio. His contribution will go towards funding the Global Polio Eradication Initiative’s (GPEI) new Polio
Eradication and Endgame Strategic Plan (2013-2018), a comprehensive six-year plan that was developed to capitalize on the unprecedented opportunity to eradicate polio.
25 April 2013:
The Bill & Melinda Gates Foundation today announced that Elizabeth Lule has been named director of the Family Planning program. She will start work at the foundation on June 17. …
Lule comes to the foundation from the World Bank where she served most recently as Regional
Integration Interim Director and Manager for the Africa Region. Prior to that, she was the World
Bank’s advisor for Population, Reproductive, Maternal, and Child Health. Prior to the World Bank, she served as Pathfinder International’s Regional Vice President for Africa where she was responsible for strategy development, fundraising and the design, management, implementation, and evaluation of
Pathfinder’s family planning, maternal and child health, and HIV programs in the region. …

U PDATE 51: A PRIL 1 TO A PRIL 30, 2013
The government today released a report showing how 48 different Norwegian actors working to ensure access to medicines and health care in the world. - Norwegian organizations have a broad commitment to global health. Government is following this up and allocate new 65 million for research on including tuberculosis and malaria, said Foreign Minister Espen Barth Eide.
The report "Norwegian actors commitment to global health" is a follow-up to the White Paper on
Global Health, which came in 2012. The report shows the breadth of Norway's commitment to improving health in the world. …
The increase from 235 million to 300 million kroner to research on including better methods for preventing maternal and child mortality, better family planning, new vaccines against tuberculosis and better drugs against malaria. …
The impressive progress made in tackling malaria across the world is in danger without sustained commitment from the international community, Lynne Featherstone said in Kinshasa today to mark
World Malaria Day. …
Global efforts to tackle the disease contributed to a 33% fall in malaria mortality rates in Africa between 2000 and 2010. However donor funding for anti-malaria programmes across the world is now levelling off and is in danger of falling over the coming years. …
The National Institutes of Health marks World Malaria Day 2013, which has the world theme Invest in the Future: Defeat Malaria, by acknowledging the considerable toll the disease continues to exact in many parts of the world. We also renew our commitment to the research needed to better understand the disease process in malaria, find new ways to diagnose and treat people with malaria, control the mosquitoes that spread it, and prevent malaria through vaccination.
Although considerable progress has been made over the past decade in the fight to control, eliminate and hopefully eradicate malaria, far too many people continue to become sick and die from this mosquito-borne disease. In 2010, 219 million cases of malaria and an estimated 660,000 malariarelated deaths occurred globally, according to the World Health Organization (WHO). Sadly, the majority of these malaria deaths were among children in Africa aged 5 years and younger. …
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of
Health, will stop administering injections in its HVTN 505 clinical trial of an investigational HIV vaccine regimen because an independent data and safety monitoring board (DSMB) found during a scheduled interim review that the vaccine regimen did not prevent HIV infection nor reduce viral load (the amount of HIV in the blood) among vaccine recipients who became infected with HIV.
The HVTN 505 study began in 2009 and was testing an investigational prime-boost vaccine regimen developed by NIAID’s Vaccine Research Center. The Phase IIb study, conducted by the NIAIDfunded HIV Vaccine Trials Network (HVTN) , was designed to determine whether the vaccine regimen could prevent HIV infection and/or reduce the amount of virus in the blood of vaccine recipients who became infected with HIV. …
Tomorrow, April 12 th , USAID will be hosting a launch event at the National Press Club for the new integrated Global Action Plan for Pneumonia and Diarrhea (GAPPD) from UNICEF and the World
Health Organization (WHO) from 8:30 a.m. to 10:30 a.m.. This event will be in conjunction with

U PDATE 51: A PRIL 1 TO A PRIL 30, 2013 launch events taking place in Geneva, and will also include the London release of The Lancet Series on pneumonia and diarrhea.
Pneumonia and diarrhea together account for 29 percent of all child deaths globally, resulting in the deaths of more than two million children each year. Countries most affected can end this staggering and unnecessary death toll by fighting the two diseases together in an integrated approach. The goal of the newly released plan is to virtually end preventable child deaths due to pneumonia and diarrhea. …
Dr Shahid Jameel has been appointed CEO of the India Alliance, an £80 million partnership between the Wellcome Trust and the Department of Biotechnology, Government of India.
Dr Jameel is Senior Scientist and Group Leader (Virology) at the International Centre for Genetic
Engineering and Biotechnology, New Delhi, and brings more than 25 years of active biomedical research and laboratory management to the India Alliance.
Launched in 2008 and operated as a joint venture, the India Alliance aims to deliver a programme of research fellowship schemes to support current and future leaders of Indian biomedical science.
…
This week sees the World Health Organization celebrating the 63rd World Health Day, held on 7 April each year to coincide with the founding of the organisation. Also this week, the Wellcome Trust launches its latest portfolio review, ‘Population and Public Health, 1990-2011’, which describes the key breakthroughs in the field over the past two decades and identifies the Trust’s role during this time.
The review is intended to help inform future funding strategy by bringing together the reflections of an expert group - chaired by Dr Jeffrey Koplan, Vice President for Global Health at Emory University,
Atlanta - with views on current challenges and future research opportunities, both for the Wellcome
Trust and for others involved in supporting population and public health research.
The global burden of dengue infection is more than triple current estimates from the World Health
Organization, according to a multinational study published online in the journal ‘Nature’.
The research has created the first detailed and up-to-date map of dengue distribution worldwide, enabling researchers to estimate the total numbers of people affected by the virus globally, regionally and nationally. The findings will help to guide efforts in vaccine, drug and vector control strategies. …
The Board of Governors of the Wellcome Trust is pleased to announce the appointment today of
Professor Jeremy Farrar as the Trust’s new Director.
Professor Farrar is an outstanding clinical scientist who has built a reputation as one of the world's leading figures in the field of infectious disease. He is currently Professor of Tropical Medicine and
Global Health at Oxford University, Global Scholar at Princeton University and Director of the
Wellcome Trust's Major Overseas Programme in Vietnam.
He will join the Wellcome Trust on 1 October, succeeding Sir Mark Walport, who stepped down at the end of March to become the Government's Chief Scientific Adviser. Dr Ted Bianco, the Trust's Director of Technology Transfer, will continue to serve as Acting Director until then. …
Resistance to the frontline antimalarial drug, artemisinin, can be identified and tracked by analysing the genetic fingerprint of parasite populations, a study published online today in ‘Nature Genetics’ demonstrates.

U PDATE 51: A PRIL 1 TO A PRIL 30, 2013
The effectiveness of this key drug is weakening, threatening hundreds of thousands of lives, and new methods of tracking resistance are vital for understanding how it could be contained.
An international team of researchers used new genetic sequencing technologies to analyse the whole genetic make-up, or genomes, of samples of the malaria-causing parasite Plasmodium falciparum.
They discovered multiple strains of the parasite that seem to be rapidly expanding throughout the local parasite population in Western Cambodia, a known hotspot for drug resistance. These strains have emerged recently and are all resistant to artemisinin.
The scientists were able to characterise distinct genetic patterns, or 'fingerprints', for each of the strains, showing the approach offers a rapid and novel way to detect and track the global emergence of drug resistance. Their findings provide important insights into how resistance emerges and is maintained by certain parasite populations. …
PDP P
R
(
A
1, 2013)
The Drugs for Neglected Diseases initiative (DNDi) Latin America today announced that it will pledge the US $100,000 Carlos Slim Health Award to Chagas disease, the leading parasitic killer of the
Americas..
“We are honoured to receive this award from the Carlos Slim Health Institute and we dedicate the prize to Chagas disease – the Americas urgently need a coordinated response and action plan to control this silent killer”, said Eric Stobbaerts, Executive Director, DNDi Latin America. “We estimate that 99% of people infected with Chagas are not even receiving treatment in the Americas and this has to change”, he added. …
“Chagas Week: Neglected Disease” gathers doctors, specialists, researchers and authorities to discuss issues related to the disease that affects up to 8 million people worldwide, mostly in Latin America, according to the World Health Organization. …
3:
Research and development (R&D) project, AfriCoLeish, is supported by the European Union Seventh
Framework Programme (EU FP7) through a grant of €3 million. The project will run for three years and aims to test new treatments for kala-azar (visceral leishmaniasis, or VL) and co-infection of the disease with HIV in Ethiopia and Sudan.
The AfricoLeish project, ‘Care Package for Treatment and Control of Visceral Leishmaniasis in East
Africa’, aims to develop and deliver a shorter combination treatment for kala-azar patients that is equally as safe and effective as the current WHO-recommended first-line treatment for the disease
(SSG&PM, sodium stibogluconate and paromomycin) in East Africa. The project also aims to determine appropriate treatment strategies for kala-azar in patients that are also HIV positive, in order to treat and also prevent repetitive relapses that are common in co-infected patients. …
Sanofi (EURONEXT, SAN and NYSE;SNY) and the Drugs for Neglected Diseases initiative (DNDi), an independent not-for-profit foundation, announce that on the occasion of World Malaria Day, more than 200 million treatments of ASAQ Winthrop have been distributed in Africa since the medication became available in 2007. …
In a genuine therapeutic and industrial innovation, the un-patented ASAQ Winthrop® treatment combines artesunate and amodiaquine in a fixed-dose combination, enabling better adherence to

U PDATE 51: A PRIL 1 TO A PRIL 30, 2013 treatment and reducing the risk of resistance development by avoiding selective use of one of the components.
Developed through an innovative partnership between DNDi and Sanofi, and manufactured by Sanofi in its Zenata plant in Morocco, ASAQ Winthrop® is now available in most malaria-affected countries, and 90% available in Africa. It is easy to use (once-a-day dose) and is available at a price of less than
US$1 for adults and $0.50 for children, for three-day treatment. …
A new study published in Nature online last week estimates that there are more than three times as many dengue infections as in the official World Health Organization (WHO) figure. The WHO estimates 50-100 million dengue infections a year, while “The global distribution and burden of
dengue” report argues that there are 390 million dengue infections per year.
According to the authors, there were an estimated 96 million apparent dengue infections, and 294 million inapparent infections, in 2010, the year on which the study was based. Apparent infections is a purposefully broad definition designed to be an inclusive measurement of the impact of symptomatic dengue on daily life, while inapparent infections represent asymptotic infections that nonetheless contribute to the spread of dengue and need to be counted due to their effect on the economic and population dynamics of dengue. …
FIND announced today the appointment of Mark Kessel to Chairman of its Board of Directors. He was appointed Vice Chair last year.
Mark Kessel co-founded Symphony Capital LLC, a private equity firm investing in the clinical development programs of biopharmaceutical companies, in 2002. He is widely recognized as the leader in structuring product development investments for the biopharmaceutical industry. Mr.
Kessel was formerly the managing partner of Shearman & Sterling, with day-to-day operating responsibility for one of the largest international law firms. He received a bachelor's degree with honors in economics from the City College of New York, and a juris doctor magna cum laude from
Syracuse University College of Law. Mr. Kessel is currently of counsel to Shearman & Sterling, and a director of Dynavax Technologies Corp., FIND and Fondation Santé. He also served as a director of the
Biotechnology Industry Organization, the Global Alliance for TB Drug Development, OXiGENE Corp.,
Antigenics Inc., Heller Financial Inc. and Harrods (UK) Limited and as a trustee of the Museum of the
City of New York. …
UNITAID, an innovative global health initiative that increases access to affordable medicines and diagnostic tests for HIV/AIDS, TB and malaria, has awarded the Foundation for Innovative New
Diagnostics (FIND) and the World Health Organization (WHO) US$ 9.4 million over five years to further expand access to quality control of malaria rapid diagnostic tests.
This UNITAID-funded project will support countries to develop their own quality control testing programmes by transferring capacity to country health programmes, thus removing dependence on external laboratories and ensuring that quality control processes are more widely available. Global product testing, on which a majority of all public sector procurement is based, will incorporate new methods with reduced costs borne predominantly by manufacturers, thus removing reliance on longterm donor support. This project will establish a model for ensuring sustainable quality control for point-of-care diagnostics in low-resource settings and could be applicable to an increasing number of other diseases as innovation in diagnostic development continues. …
Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has partnered with the Foundation for Innovative New Diagnostics (FIND) to develop a rapid,

U PDATE 51: A PRIL 1 TO A PRIL 30, 2013 high-throughput malaria diagnostic assay for screening patients in the developing world.
The partnership will allow FIND to access Lumora’s technologies such as BART (Bioluminescent Assay in Real Time) and the company’s expertise to develop a novel test that will allow rapid screening on a large scale.
Strategies for the elimination of malaria are held back by lack of screening technologies for use in the field that can detect hidden or low parasitemia malaria infections, and thus stamp out the final cases.
Such screening would also then help to keep these populations malaria free. The first field test with sufficient sensitivity to detect as few as one malaria parasite in a finger-prick blood sample has recently been developed and released by FIND and Eiken Chemical (Japan). The partnership with
Lumora, funded by the BMBF of Germany, will enable the malaria LAMP test to be scaled into a highthroughput screening test specifically designed for malaria elimination programmes. …
1 April 2013:
The International AIDS Vaccine Initiative (IAVI) and DNAVEC announce the start of a multi-center
Phase I clinical trial to evaluate the safety and tolerability of a novel preventive HIV vaccine candidate,
SeV-G. Researchers also seek to obtain a preliminary assessment of the immune responses elicited by a prime-boost regimen of SeV-G and a vaccine candidate based on adenovirus serotype 35. This clinical trial is the first ever to test SeV-G.
Vaccinations in the trial, which is sponsored by IAVI, commenced today at Projet San Francisco in
Kigali, Rwanda. The trial will also be conducted at the St. Stephen’s Center in London, United Kingdom and, pending final approval, at an additional research center in East Africa. 
 Developed by IAVI and the Japanese biotechnology company DNAVEC, SeV-G is a novel, replicating viral vector that targets mucosal tissues. It is derived from a weakened form of the Sendai virus, a virus related to the measles and canine distemper viruses. It ordinarily infects rodents, and is not known to cause human disease.
The SeV-G vector carries the gene for the gag protein of HIV as a vaccine antigen. Unlike the vast majority of HIV vaccine vectors evaluated in trials so far, SeV-G retains the ability to multiply inside the human body. Researchers expect that replicating vectors might be able to elicit immune responses that are broader, longer lasting and more potent than those elicited by non-replicating vectors bearing similar HIV antigens.
On the 6 th World Malaria Day, MMV and the World Health Organization’s Global Malaria Programme
(WHO/GMP) launch the Global Malaria Mapper – a newly-designed mapping tool that allows users to build customized maps using data from WHO’s World Malaria Report.
Malaria occurs in 99 countries worldwide, exacting a heavy toll on human health and imposing a major social and economic burden on endemic countries, particularly in sub-Saharan Africa. A recent expansion of malaria interventions – including a scale up of mosquito control measures, diagnostic testing and treatment – has contributed to a significant decrease in the malaria burden around the world. The World Malaria Report is an annual report containing comprehensive data and analysis on the malaria situation in all endemic countries.
To make this enormous amount of data visually accessible and easier to understand, MMV has worked with Comstone (for design), MeDev (for web development) and WHO/GMP to develop a new interactive online tool. Unlike paper atlases, the Global Malaria Mapper allows users to create maps illustrating a range of themes, including epidemiological profiles for countries and regions, reported cases and deaths, laboratory confirmation, or the scale-up of interventions within a given geographical location. All this at the click of a button.
Sanofi (Euronext: SAN and NYSE: SNY) and PATH’s Drug Development program, established through

U PDATE 51: A PRIL 1 TO A PRIL 30, 2013 an affiliation with OneWorld Health, today announced the launch of the large-scale production line of semisynthetic artemisinin at Sanofi’s Garessio site in Italy. …
The innovative industrial process to produce semisynthetic artemisinin consists in the production of artemisinic acid through fermentation—which is performed by Huvepharma, in Bulgaria—followed by a synthetic transformation of the artemisinic acid into artemisinin via photochemistry, which will be performed at Sanofi’s Garessio site. Sanofi plans to produce 35 tons of artemisinin in 2013 and, on average, 50 to 60 tons a year by 2014, which corresponds to between 80 and 150 million ACT treatments. …
As Product Development Partnerships (PDPs) dedicated to the discovery, development and delivery of new global health tools, we applaud the official launch of the Global Health Innovation and
Technology Fund (GHIT Fund), which was announced today in Tokyo, Japan. This new public-private partnership of the Japanese Government, the Bill & Melinda Gates Foundation and a group of private pharmaceutical companies seeks to foster and harness Japanese innovation to address diseases that disproportionately affectlow- and middle-income countries. …
R
PDP
/
/

Nonclinical Development of BCG Replacement Vaccine Candidates.
Velmurugan K et al. Vaccines
2013. 1(2), 120-138.

Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa.
Chandra RS et al. Malaria Journal 2013, 12:122 doi:10.1186/1475-2875-12-122

CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human
CD8 + CD39 + regulatory T cells.
Boer MC et al. European Journal of Immunology.
DOI: 10.1002/eji.201243286

Yellow Fever Vaccination: The Potential of Dose-Sparing to Increase Vaccine Supply and
Availability.
PATH. April 2013.
R
PDP
/
/
 University Global Health Impact Report Card.
Project of the Universities Allied for Essential
Medicines. April 2013.

Economic Appraisals for Product Development Partnership.
Report from the PDP Access group meeting in January 2013. April 2013.
 Decade of Vaccines Supplement.
Vaccine Volume 31, Supplement 2, Pages B1-B250 (April 2013)

Management of severe malaria – A practical handbook.
WHO Global Malaria Programme. April
2013

Integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea.
WHO
& UNICEF. April 2013

Childhood Pneumonia and Diarrhoea.
The Lancet. Special Supplement. Published April 12 2013.
 Polio Eradication and Endgame Strategic Plan 2013–2018.
Global Polio Eradication Initiative. April
2013.
PDP R
N
/ A
(
A
1, 2013)

Rational HIV immunogen design to target specific germline B cell receptors.
Jardine

U PDATE 51: A PRIL 1 TO A PRIL 30, 2013
J et al. Science, 28 March 2013 DOI: 10.1126/science.1234150

HIV: Roadmaps to a vaccine.
Mouquet H & Nussenzweig. Nature (2013) doi:10.1038/nature12091. Published online 03 April 2013
 HIV-1 prevention with ART and PrEP: mathematical modeling insights into resistance, effectiveness and public health impact.
Celum C et al. Journal of
Infectious Diseases. 9 April 2013

Microbicide clinical trial adherence: Insights for introduction.
Woodsong C et al. J
Intl AIDS Society. 8 April 2013

Antiretroviral therapy and pre-exposure prophylaxis: Combined impact on HIV-1 transmission and drug resistance in South Africa.
Abbas U et al. Journal of
Infectious Diseases. 9 April 2013
 Appropriateness of hydroxyethylcellulose gel as a placebo control in vaginal microbicide trials: A comparison of the two control arms of HPTN 035.
Richardson B et al. JAIDS. 12 April 2013; 63(1):120-125.

Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies.
Etter P et al. AIDS. 24
April 2013; 27(7):1119-1128.

Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in
Uganda: Results from the first HIV vaccine trial in infants in Africa.
Kindu K et al.
JAIDS. 1 May 2013; 63(1):1-8.

Community viral load as a measure for assessment of HIV treatment as prevention .
Miller W et al. The Lancet Infectious Diseases. 30 April 2013; 13(5):459-464.

Microbicides from a regulatory perspective.
Stone A et al. AIDS. 24 April 2013
[Epub ahead of print]

3 April: Possible path to vaccine for AIDS is suggested

8 April: Origami condoms radically redesigns almost century-old latex protection
 Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.
Bejon P et al. The Lancet Infectious Diseases, Volume 13, Issue 4, Pages 319 -
327, April 2013

Assessment of the RTS,S/AS01 malaria vaccine.
Moothy VS et al. The Lancet
Infectious Diseases, Volume 13, Issue 4, Pages 280 - 282, April 2013
 24 April: WHO launches emergency response to antimalarial drug resistance

25 April: World Malaria Day 2013: malaria in pregnancy studies and future research capacity

Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.
Lawn SD et al. The Lancet Infectious Diseases,
Volume 13, Issue 4, Pages 349 - 361, April 2013

Tuberculosis biomarkers discovery: developments, needs, and challenges.
Wallis RS et al. The Lancet Infectious Diseases, Volume 13, Issue 4, Pages 362 - 372, April
2013

The global distribution and burden of dengue.
Bhatt S et al. Nature (2013) doi:10.1038/nature12060 Published online 07 April 2013

Global economic burden of Chagas disease: a computational simulation model.
Lee
BL et al. The Lancet Infectious Diseases, Volume 13, Issue 4, Pages 342 - 348, April
2013

23 April: Researchers discover possible new approach to combating dengue fever

5 April: Biomedical research fellowship aims to build capacity in Africa

8 April: Japanese pharma companies to help medicine research in developing countries

11 April: U.S. Department of Commerce Announces Patents for Humanity Winners

12 April: WHO/UNICEF: New plan to address pneumonia and diarrhoea could save
2 million children a year

12 April: Sires Introduces Legislation to Support Global Health Research and
Development

18 April: Better supply systems key to reach all children with life-saving vaccines

U PDATE 51: A PRIL 1 TO A PRIL 30, 2013

25 April: Global leaders support new six-year plan to deliver a polio-free world by
2018

26 April: Stakeholder meetings: strategic and research priorities for EDCTP2

29 April: GHTC launches database on global health regulatory requirements
U
M

June 4-5 2013: A Decade of R&D for Neglected Diseases in Africa Endemic Country Research and
Development for Patient Access.
Meeting organized by DNDi and KEMRI, Nairobi, Kenya
